Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval

References

• Cancer IAfRoGlobocan2002 http://www-dep.iarc.fc/Accessed June 21, 2011
   Google Scholar
• SorlieTTibshiraniRParkerJRepeated observation of breast tumor subtypes in independent gene expression data setsProc Natl Acad Sci U S A2003100148418842312829800
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• SchiffPBFantJHorwitzSBPromotion of microtubule assembly in vitro by taxolNature19792775698665667423966
   PubMed Web of Science ®Google Scholar
• RingelIHorwitzSBStudies with RP 56976 (taxotere): a semisynthetic analogue of taxolJ Natl Cancer Inst19918342882911671606
   PubMedGoogle Scholar
• De LaurentiisMCancelloGD’AgostinoDTaxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trialsJ Clin Oncol2008261445318165639
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJBurzykowskiTBuyseMTaxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerJ Clin Oncol200826121980198618421049
   PubMed Web of Science ®Google Scholar
• GradisharWJAlbumin-bound paclitaxel: a next-generation taxaneExpert Opin Pharmacother2006781041105316722814
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317794780316172456
   PubMed Web of Science ®Google Scholar
• WaniMCTaylorHLWallMECoggonPMcPhailATPlant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJ Am Chem Soc1971939232523275553076
   PubMed Web of Science ®Google Scholar
• RowinskyEKCazenaveLADonehowerRCTaxol: a novel investigational antimicrotubule agentJ Natl Cancer Inst19908215124712591973737
   PubMed Web of Science ®Google Scholar
• MieleESpinelliGPTomaoFTomaoSAlbumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerInt J Nanomedicine200949910519516888
   PubMed Web of Science ®Google Scholar
• WindebankAJBlexrudMDde GroenPCPotential neurotoxicity of the solvent vehicle for cyclosporineJ Pharmacol Exp Ther19942682105110568113961
   PubMed Web of Science ®Google Scholar
• AuthierNGilletJPFialipJEschalierACoudoreFDescription of a short-term Taxol-induced nociceptive neuropathy in ratsBrain Res2000887223924911134612
   PubMed Web of Science ®Google Scholar
• ten TijeAJVerweijJLoosWJSparreboomAPharmacological effects of formulation vehicles: implications for cancer chemotherapyClin Pharmacokinet200342766568512844327
   PubMed Web of Science ®Google Scholar
• WindebankAJThe vehicle for cyclosporine is neurotoxic in vitroAnn Neurol19974145635649124820
   PubMed Web of Science ®Google Scholar
• AuthierNGilletJPFialipJEschalierACoudoreFAssessment of neurotoxicity following repeated cremophor/ethanol injections in ratsNeurotox Res20013330130615111255
   PubMed Web of Science ®Google Scholar
• SparreboomAvan ZuylenLBrouwerECremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsCancer Res19995971454145710197613
   PubMed Web of Science ®Google Scholar
• WinerEPBerryDAWoolfSFailure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342J Clin Oncol200422112061206815169793
   PubMed Web of Science ®Google Scholar
• CurrySMandelkowHBrickPFranksNCrystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sitesNat Struct Biol1998598278359731778
   PubMedGoogle Scholar
• HerveFUrienSAlbengresEDucheJCTillementJPDrug binding in plasma. A summary of recent trends in the study of drug and hormone bindingClin Pharmacokinet199426144588137597
   PubMed Web of Science ®Google Scholar
• CarverLASchnitzerJECaveolae: mining little caves for new cancer targetsNat Rev Cancer20033857158112894245
   PubMed Web of Science ®Google Scholar
• JohnTAVogelSMTiruppathiCMalikABMinshallRDQuantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayerAm J Physiol Lung Cell Mol Physiol20032841L187L19612471015
   PubMed Web of Science ®Google Scholar
• MinshallRDSessaWCStanRVAndersonRGMalikABCaveolin regulation of endothelial functionAm J Physiol Lung Cell Mol Physiol20032856L1179L118314604847
   PubMed Web of Science ®Google Scholar
• TiruppathiCSongWBergenfeldtMSassPMalikABGp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathwayJ Biol Chem19972724125968259759325331
   PubMed Web of Science ®Google Scholar
• VogelSMMinshallRDPilipovicMTiruppathiCMalikABAlbumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding proteinAm J Physiol Lung Cell Mol Physiol20012816L1512L152211704548
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089
   PubMed Web of Science ®Google Scholar
• IbrahimNKDesaiNLeghaSPhase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxelClin Cancer Res2002851038104412006516
   PubMed Web of Science ®Google Scholar
• SparreboomAScriptureCDTrieuVComparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)Clin Cancer Res200511114136414315930349
   PubMed Web of Science ®Google Scholar
• GardnerERDahutWLScriptureCDRandomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxelClin Cancer Res200814134200420518594000
   PubMed Web of Science ®Google Scholar
• NymanDWCampbellKJHershEPhase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignanciesJ Clin Oncol200523317785779316258082
   PubMed Web of Science ®Google Scholar
• YamadaKYamamotoNYamadaYMukoharaTMinamiHTamuraTPhase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumorsJpn J Clin Oncol201040540441120133335
   PubMed Web of Science ®Google Scholar
• IbrahimNKSamuelsBPageRMulticenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancerJ Clin Oncol2005Sep 12325:6019602616135470
   PubMed Web of Science ®Google Scholar
• BlumJLSavinMAEdelmanGPhase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanesClin Breast Cancer200771185085618269774
   PubMed Web of Science ®Google Scholar
• GradisharWJKrasnojonDCheporovSSignificantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerJ Clin Oncol200927223611361919470941
   PubMed Web of Science ®Google Scholar
• RoyVLaPlantBRGrossGGBaneCLPalmieriFMPhase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)Ann Oncol200920344945319087987
   PubMed Web of Science ®Google Scholar
• SomerBDSchwartzbergLSArenaFEppersonAFuDFortnerBVPhase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I20072518S1053
   Google Scholar
• DansoMABlumJLRobertNJPhase II trial of weekly nabpaclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancerJ Clin Oncol2008May 20Suppl 26 Abstr 1075
   Google Scholar
• LoboCLopesGBaezOFinal results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerBreast Cancer Res Treat2010123242743520585851
   PubMed Web of Science ®Google Scholar
• ConlinAKHudisCABachARandomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)J Clin Oncol200927Suppl 15 Abstr 1006
   Google Scholar
• ConlinAKSeidmanADBachAPhase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerClin Breast Cancer201010428128720705560
   PubMed Web of Science ®Google Scholar
• MirtschingBCosgriffTHarkerGKeatonMChidiacTMinMA Phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancerClin Breast Cancer201111212112821569998
   PubMed Web of Science ®Google Scholar
• YardleyDBurrisH3rdPeacockNA pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancerBreast Cancer Res Treat2010123247147520658263
   PubMed Web of Science ®Google Scholar
• RobertNKrekowLStokoeCClawsonAIglesiasJO’ShaughnessyJAdjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot studyBreast Cancer Res Treat2011125111512020945091
   PubMed Web of Science ®Google Scholar
• McArthurHLRugoHNulsenBA feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerClin Cancer ResFeb 242011
   Web of Science ®Google Scholar
• RobidouxABuzdarAUQuinauxEA phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancerClin Breast Cancer2010101818620133263
   PubMed Web of Science ®Google Scholar
• YardleyDAZubkusJDanielBA phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancerClin Breast Cancer201010536737220670921
   PubMed Web of Science ®Google Scholar
• KaklamaniVGSiziopikouKScholtensDPilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinibBreast Cancer Res TreatFeb 272011
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKBarniSTargeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxelExpert Opin Pharmacother20101181413143220446855
   PubMed Web of Science ®Google Scholar
• SeidmanADBerryDCirrincioneCRandomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840J Clin Oncol200826101642164918375893
   PubMed Web of Science ®Google Scholar
• RobertNJDierasVGlaspyJRIBBON-1: randomized, double- blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor Receptor 2-negative, locally recurrent or metastatic breast cancerJ Clin Oncol201129101252126021383283
   PubMed Web of Science ®Google Scholar
• GuanZFengFLiQLRandomized study comparing nabpaclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC)Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I2007Jun 2025Suppl 181038
   Google Scholar
• PazIBLauSGarberoglioCNab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II–III breast cancer (BC)J Clin Oncol2008May 20Suppl 26Abstr 567
   Web of Science ®Google Scholar
• YardleyDARaefskyECastilloRResults of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlativesJ Clin Oncol200927Suppl 15 Abstr 527
   Web of Science ®Google Scholar